Skip to main
VVOS

Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics (VVOS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivos Therapeutics is experiencing an increase in gross margins, leading to a revision in estimates for fiscal year 2026. With a higher share count and operating expenses, the company's stock price has decreased, but the multi-billion dollar market potential and opportunities for growth through acquisitions provide potential for high returns. However, there are risks, such as low visibility on revenues and the need for further financing to sustain growth.

Bears say

Vivos Therapeutics is a medical technology company that recently reported its 2025 financial results, showing a 16% increase in revenue, but also a higher than expected net loss. The company has faced challenges with provider attrition and has had to implement cost-saving measures, which could lead to improved operational efficiency. However, there are still risks to achieving the company's price target, including the need for additional capital and potential competition from other sleep apnea treatment options.

Vivos Therapeutics (VVOS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivos Therapeutics (VVOS) Forecast

Analysts have given Vivos Therapeutics (VVOS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Vivos Therapeutics (VVOS) has a Strong Buy consensus rating as of Sep 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivos Therapeutics (VVOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.